Combination paclitaxel and inhibitor of nuclear factor κb activation improves therapeutic outcome for model mice with peritoneal dissemination of pancreatic cancer

Pancreas

Volumn 40, Issue 4, 2011, Pages 600-607

  Fujiwara, Yuki ^a   Furukawa, Kenei ^a   Shimada, Yohta ^a   Iida, Tomonori ^a   Shiba, Hiroaki ^a   Uwagawa, Tadashi ^a   Misawa, Takeyuki ^a   Ohashi, Toya ^a   Yanaga, Katsuhiko ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

intraperitoneal chemotherapy; Nafamostat mesilate; paclitaxel; pancreatic cancer; peritoneal dissemination

Indexed keywords

CASPASE 8; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NAFAMSTAT MESILATE; PACLITAXEL; TUMOR MARKER;

ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PERITONEUM METASTASIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 8; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; DRUG SYNERGISM; GUANIDINES; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NF-KAPPA B; PACLITAXEL; PANCREATIC NEOPLASMS; PERITONEUM; PHOSPHORYLATION; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79955056566     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31820b9257     Document Type: Article

References (48)

1. Evans DB, Abbruzzesse JL, Willett CG. Cancer of the pancreas. In: De Vita VT, Hellman S, Rosenberg SA, eds. Cancer - Principles and Practice of Oncology. 6th ed. Lippincott Williams and Wilkins; 2001:1126-1161.
2. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15:2403-2413. (Pubitemid 27251144)
3. Burris H, Storniolo AM. Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer. 1997; 33(suppl 1):S18-S22.
4. Abou-Alfa GK, Letourneau R, Harker G, et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol. 2006; 20:4441-4447. (Pubitemid 46630982)
5. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma. Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002; 20:3270-3275. (Pubitemid 34831525)
6. Yoo CH, Noh SH, Shin DW, et al. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000; 87:236-242. (Pubitemid 30088655)
7. Chan JK, Tian C, Monk BJ, et al. Gynecologic Oncology Group. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer. 2008; 112:2202-2210. (Pubitemid 351628630)
8. Nakachi K, Furuse J, Ishii H, et al. Prognostic factors in patients with gemcitabine-refractory pancreatic cancer. Jpn J Clin Oncol. 2007; 37:114-120. (Pubitemid 47090708)
9. Ajani JA, Fairweather J, Dumas P, et al. Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am. 1998; 4:269-274.
10. Rowinsky EK. Update on the antitumor activity of pacitaxel in clinical trials. Ann Pharmacother. 1994; 28:S18-S22. (Pubitemid 24139916)
11. Yonemura Y, Bando E, Kawamura T, et al. Cytoreduction and intraperitoneal chemotherapy for carcinomatosis from gastric cancer. Cancer Treat Res. 2007; 134:357-373.
12. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006; 354:34-43. (Pubitemid 43048949)
13. Chen F, Castranova V, Shi X. New insights into the role of nuclear factor-κ B in cell growth regulation. Am J Pathol. 2001; 159:387-397. (Pubitemid 32751067)
14. Beg AA, Baltimore D. An essential role for NF-kB in preventing TNF-α -induced cell death. Science. 1996; 274:782-784. (Pubitemid 26398258)
15. Van ADJ, Martin SJ, Kafri T, et al. Suppression of TNF-α -induced apoptosis by NF-κ B. Science. 1996; 274:787-789.
16. Karin M, Lin A. NF-κ B at the crossroads of life and death. Nature Immunol. 2002; 3:221-227.
17. Weixin W, James LA, Douglas BE, et al. The nuclear factor-kB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res. 1999; 5:119-127.
18. Fujioka S, Sclabas GM, Schmidit C, et al. Inhibition of constitutive NF-κ B activity by Iκ Bα M suppresses tumorigenesis. Oncogene. 2003; 22:1365-1370. (Pubitemid 36384598)
19. Fujioka S, Sclabas GM, Schmidit C, et al. Function of nuclear kB in pancreatic cancer metastasis. Clin Cancer Res. 2003; 9:346-354. (Pubitemid 36109751)
20. Wang CY, Cusack JC Jr, Liu R, et al. Control of inducible chemoresistance: enhanced antitumor therapy through increased apoptosis by inhibition of NF-κ B. Nat Med. 1999; 5:412-417. (Pubitemid 29180579)
21. Yeh PY, Chuang SE, Yeh KH, et al. Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement anticancer drug-induced NFκ B activation. Biochem Pharmacol. 2002; 63: 1423-1430. (Pubitemid 34457957)
22. Patel NM, Nozaki S, Shortle NH, et al. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κ B is enhanced by Iκ Bα super-repressor and parthenolide. Oncogene. 2000; 19:4159-4169.
23. Dong QG, Sclabas GM, Fujioka S, et al. The function of multiple Iκ B: NF-κ B complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene. 2002; 21:6510-6519. (Pubitemid 35155455)
24. Oyaizu H, Adachi Y, Okumura T, et al. Proteasome inhibitor 1 enhances paclitaxel-induced apoptosis in human lung adenocarcinoma cell line. Oncol Rep. 2001; 8:825-829.
25. Fujii S, Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, kallikrein and trypsin. Biochim Biophys Acta. 1981; 661:342-345. (Pubitemid 12233442)
26. Aoyama T, Ino Y, Ozeki M, et al. Pharmacological studies of FUT-175, nafamostat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol. 1984; 35:207-227.
27. Iwaki M, Ino Y, Motoyoshi A, et al. Pharmacological studies of FUT-175, nafamostat mesilate. IV. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats. Jpn J Phamacol. 1986; 41:155-162. (Pubitemid 16078701)
28. Takahashi H, Takizawa S, Tatewaki W, et al. Nafamostat mesilate (FUT-175) in the treatment of patients with disseminated intravascular coagulations. Thomb Haemost. 1989; 62:372.
29. Ohtake Y, Hirasawa H, Sugai T, et al. Nafamostat mesilate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contr Nephrol. 1991; 93:215-217.
30. Uwagawa T, Li Z, Chang Zhe, et al. Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death. Cancer. 2007; 109:2142-2153. (Pubitemid 46744211)
31. Uwagawa T, Chiano PJ, Gocho T, et al. Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-κ B activation. Anticancer Res. 2009; 29:3173-3178.
32. Uwagawa T, Misawa T, Sakamoto T, et al. A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. Ann Oncol. 2009; 20:239-243.
33. Shimada Y, Fukuda T, Aoki K, et al. A protocol for immunoaffinity separation of the accumulated ubiquitin-protein conjugates solubilized with sodium dodecyl sulfate. Anal Biochem. 2008; 377:77-82.
34. Rowinsky EK. Update on the antitumor activity of paclitaxel in clinical trials. Ann Pharmacother. 1994; 28:S18-S22. (Pubitemid 24139916)
35. Schiff PB, Faut J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature (Lond). 1979; 277:665-667. (Pubitemid 9114288)
36. Kumar N. Taxol-induced polymerization of purified tubulin: mechanism of action. J Biol Chem. 1981; 256:10435-10441. (Pubitemid 12219438)
37. Schiff PB, Horwitz SB. Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins. Biochemistry. 1981; 20:3247-3252.
38. Rowinsky EK, Donehower RC, Jones RJ, et al. Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Res. 1988; 48:4093-4100.
39. Horwitz SB. Mechanism of action taxol. Trends Pharmacol Sci. 1992; 13:134-136.
40. Tanaka R, Ariyama H, Qin B, et al. In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol. 2005; 55:565-601.
41. Koutcher JA, Motwani M, Zakian KL, et al. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow. Clin Cancer Res. 2000; 6:1498-1507. (Pubitemid 30226239)
42. Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer Treat Res. 1996; 82:53-63.
43. Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet. 1994; 344:1267-1272. (Pubitemid 24334685)
44. Markman M. Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity. Cancer Treat Rev. 1986; 13:219-242. (Pubitemid 17020165)
45. Wang CY, Mayo MW, Korneluk RG, et al. NF-κ B antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998; 281:1680-1683.
46. Mabuchi S, Ohmichi M, Nishio Y, et al. Inhibition of Inhibitor of nuclear factor-κ B phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin Cancer Res. 2004; 10:7645-7654. (Pubitemid 39557528)
47. Aggarwal BB, Shishodia S, Takada Y, et al. Curcumin suppresses the paclitaxel-induced nuclear factor-κ B pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res. 2005; 11:7490-7498. (Pubitemid 41507710)
48. Inoue M, Matsumoto S, Saito H, et al. Intraperitoneal administration of a small interfering RNA targeting nuclear factor-κ B with paclitaxel successfully prolongs the survival of xenograft model mice with peritoneal metastasis of gastric cancer. Int J Cancer. 2008; 123:2696-2701.